NCT07038096View on ClinicalTrials.gov

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Small Cell Lung CancerNeuroendocrine Carcinoma
Interventions
DRUG

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

DRUG

ZG005

ZG005 will be administered as an intravenous (IV) infusion.

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY